A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-Month results from FACTS-International

International Journal of Clinical Practice

Volumn 62, Issue 4, 2008, Pages 575-584

  Reid, D M ^a   Hosking, D ^b   Kendler, D ^c   Brandi, M L ^d   Wark, J D ^e   Marques Neto, J F ^f   Weryha, G ^g   Verbruggen, N ^h   Hustad, C M ^h   Mahlis, E M ^h   Melton, M E ^h  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c Providence Health Care Canada   (Canada)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g CHU NANCY BRABOIS   (France)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AS CAL; BIOLOGICAL MARKER; CALCIUM CARBONATE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEMUR TROCHANTERIC FRACTURE; GASTROINTESTINAL SYMPTOM; GEOMETRY; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UPPER GASTROINTESTINAL TRACT;

EID: 40449130463     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01704.x     Document Type: Article

References (43)

1. 1 Poole KES, Compston JE. Osteoporosis and its management. BMJ 2006 ; 333: 1251–6.
2. 2 Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000 ; 85: 231–6.
3. 3 Hochberg MC, Greenspan S, Wasnich RD et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 ; 87: 1586–92.
4. 4 Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999 ; 42: 1246–54.
5. 5 Bauer DC, Black DM, Garnero P et al. Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate‐treated women: the Fracture Intervention Trial. J Bone Miner Res 2004 ; 19: 1250–8.
6. 6 Cummings SR, Karpf DB, Harris F et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002 ; 112: 281–9.
7. 7 Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001 ; 20: 3175–88.
8. 8 Marcus R, Wong M, Heath H 3rd et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002 ; 23: 16–37.
9. 9 Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti‐resorptive therapy. Bone 2004 ; 34: 599–604.
10. 10 Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005 ; 21: 545–53.
11. 11 Cummings SR, Black DM, Thompson DE et al. Alendronate reduces the risk of vertebral fractures in women without preexisting vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 ; 280: 2077–82.
12. 12 Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995 ; 333: 1437–43.
13. 13 Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994 ; 79: 1693–700.
14. 14 Bone HG, Hosking D, Devogelaer J‐P et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004 ; 350: 1189–99.
15. 15 Cranney A, Wells G, Willan A et al. Meta‐analyses of therapies for postmenopausal osteoporosis. II. Meta‐analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002 ; 23: 508–16.
16. 16 Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003 ; 14: 2–12.
17. 17 Levis S, Quandt SA, Thompson D et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention Trial. J Am Geriatr Soc 2002 ; 50: 409–15.
18. 18 Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000 ; 85: 4118–24.
19. 19 Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999 ; 9: 461–8.
20. 20 Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999 ; 282: 1344–52.
21. 21 Cranney A, Tugwell P, Adachi J et al. Meta‐analyses of therapies for postmenopausal osteoporosis. III. Meta‐analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002 ; 23: 517–23.
22. 22 Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non‐vertebral fractures: review and meta‐analysis of intention‐to‐treat studies. Osteoporos Int 2005 ; 16: 1291–8.
23. 23 Cranney A, Guyatt G, Griffith L et al. Meta‐analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta‐analysis of therapies for postmenopausal women. Endocr Rev 2002 ; 23: 570–7.
24. 24 Kanis JA, Oden A, Johnell O et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002 ; 13: 443–9.
25. 25 McAlister FA, Laupacis A, Wells GA et al. Users’ Guides to the medical literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999 ; 282: 1371–7.
26. 26 Bucher HC, Guyatt GH, Cook DJ et al. Users’ Guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints. Evidence‐based medicine working group. JAMA 1999 ; 282: 771–8.
27. 27 Hosking D, Adami S, Felsenberg D et al. Comparison of change in bone resorption and bone mineral density with once weekly alendronate and daily risedronate. Curr Med Res Opin 2003 ; 19: 383–94.
28. 28 Rosen C, Hochberg M, Bonnick S et al. Treatment with once‐weekly alendronate 70 mg compared to once‐weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double‐blind study. J Bone Miner Res 2005 ; 20: 141–51.
29. 29 Reid DM, Hosking D, Kendler D et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS‐international. Clin Drug Investig 2006 ; 26: 63–74.
30. 30 Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000 ; 67: 277–85.
31. 31 Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 ; 18: 1051–6.
32. 32 Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 2006 ; 21: 292–9.
33. 33 Blake GM, Fogelman I. Role of dual‐energy X‐ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007 ; 10: 102–10.
34. 34 Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003 ; 9: 10–5.
35. 35 Bonnick SL. Current controversies in bone densitometry. Curr Opin Rheumatol 2002 ; 14: 416–20.
36. 36 Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007 ; 18: 25–34.
37. 37 Black DM, Rosen CJ. Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? Nat Clin Pract Rheumatol 2007 ; 3: 378–9.
38. 38 Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006 ; 21: 349–53.
39. 39 Eisman JA, Rizzoli R, Roman‐Ivorra J et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double‐blind, placebo‐controlled study. Curr Med Res Opin 2004 ; 20: 699–705.
40. 40 Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002 ; 1: 71–8.
41. 41 Taggart H, Bolognese MA, Lindsay R et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002 ; 77: 262–70.
42. 42 Greenspan S, Field‐Munves E, Tonino R et al. Tolerability of once‐weekly alendronate in patients with osteoporosis: a randomized, double‐blind, placebo‐controlled study. Mayo Clin Proc 2002 ; 77: 1044–52.
43. 43 Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long‐term bisphosphonate treatment. Curr Med Res Opin 2004 ; 20: 1291–300.